Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
completion around

Description

Summary

The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome.

Official Title

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome (POETYK SjS-1)

Keywords

Sjögren's Syndrome, Deucravacitinib, Sjogren's Syndrome, BMS-986165, POETYK, Sjogren Syndrome, Sjogren-Larson Syndrome, Gougerot-Sjogren, Gougerot Sjogren Syndrome, Sjogren, Sjogren's, Sjogren Disease, Sjogren's Disease, Syndrome

Eligibility

Locations

  • UCSF Univ of California San Francisco accepting new patients
    San Francisco California 94143 United States
  • Providence St. John's Health Center accepting new patients
    Santa Monica California 90404 United States
  • Local Institution - 0228 not yet accepting patients
    Fullerton California 92835 United States
  • Arthritis and Osteoporosis Medical Center accepting new patients
    La Palma California 90623 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Bristol-Myers Squibb
Links
BMS Clinical Trial Information BMS Clinical Trial Patient Recruiting
ID
NCT05946941
Phase
Phase 3 Sjögren Syndrome Research Study
Study Type
Interventional
Participants
Expecting 756 study participants
Last Updated